Infliximab for the treatment of disseminated pyoderma gangrenosum associated with ulcerative colitis. Case report and literature review.
We report the case of a 19-year-old woman who developed an acute disseminated pyoderma gangrenosum (PG) during a severe flare of ulcerative colitis (UC). She was successfully treated with a 3-dose regimen of the anti-tumor-necrosis-factor-alpha antibody infliximab. The literature on the effectiveness of this biological agent was reviewed, including 8 other cases of UC-associated PG and 77 cases of Crohn's-disease-associated PG. This case report and the review of the literature demonstrate that infliximab can be successfully used to treat patients with PG associated with inflammatory bowel diseases.
Juillerat
Pascal
P
Division of Gastroenterology and Hepatology, University of Lausanne, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
Christen-Zäch
Stephanie
S
Troillet
François-Xavier
FX
Gallot-Lavallée
Suzanne
S
Pannizzon
Renato G
RG
Michetti
Pierre
P
D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D003093:Colitis, Ulcerative / Q000150:complications*; D003879:Dermatologic Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D000069285:Infliximab; D017511:Pyoderma Gangrenosum / Q000188:drug therapy* / Q000209:etiology